CAMBRIDGE, Mass., Jan. 26, 2021 /PRNewswire/ -- Senda
Biosciences, a therapeutics platform company creating novel
categories of medicines based on a new field of science called
Intersystems Biology, announced today that it has entered into a
strategic collaboration with Nestlé Health Science for the
development of novel nutritional therapies for a wide range of
metabolic conditions, including obesity and glycemia.
The companies will focus initially on accelerating
first-in-human clinical studies on up to three small molecule
compounds developed by Senda, leveraging the capabilities of Nestlé
Health Science, a global leader in the science of nutrition. The
compounds have been rationally designed based on Senda's
Intersystems Biology discovery platform, and screened through
Senda's proprietary bioassays for their potential to improve
metabolic health. In preclinical studies these compounds have shown
the ability to achieve sustained reductions in weight, as well as
improvements in glucose clearance and liver health.
"We are thrilled to partner with Nestlé Health Science, which
has deep expertise in nutritional health and a global reach, to
rapidly bring these breakthrough metabolic health products to as
many people as possible," said Guillaume
Pfefer, CEO of Senda Biosciences. "By bringing together the
complementary capabilities of our two organizations, we will
accelerate the development of these nutritional therapies, while at
the same time expanding their vast potential. The collaboration
will also enable Senda to advance its first therapies into in-human
clinical trials, and further validate Intersystems Biology, a field
Senda is pioneering."
Senda's Intersystems Biology discovery platform combines
extensive human sampling of previously uncharted tissues with
advanced computational biology to generate novel, actionable
insights into the trillions of interspecies molecular connections
in the human body. It harnesses the power of this pharmacy within
us to develop novel pharmacological and nutritional approaches.
Under the terms of the agreement, the two companies will
collaborate on the development and commercialization of these
compounds for metabolic health, with Senda granting Nestlé Health
Science exclusive global commercialization rights in the
nutritional field. The agreement also enables further collaboration
on development of a prescription therapeutic, with Senda retaining
therapeutic ownership rights.
"This collaboration brings together Nestlé Health Science's
extensive knowledge and commitment to redefining the management of
health with Senda's one-of-a-kind approach to medicines discovery
and development," said Nestlé Health Science Chief Medical and
Scientific Officer Hans-Juergen
Woerle. "Together we can create solutions with the potential
to transform the lives of people who live with a wide range of
metabolic health conditions."
Senda Biosciences is pioneering the field of
Intersystems Biology to create novel medicines. Intersystems
Biology focuses on how molecular connections among botanical,
bacterial, and human cells—coevolved over millennia—define health
and disease. Senda's Intersystems Biology discovery platform, which
combines extensive human sampling of previously uncharted tissues
with advanced computational biology, has been able to generate
novel, actionable insights into the trillions of interspecies
molecular connections in the human body – and it harnesses the
power of this pharmacy within us with novel pharmacological
approaches. The power and productivity of the Senda platform is
illustrated by 5 preclinical programs across oncology, neurology,
chronic disease, and metabolic disease. Senda was founded by the
life sciences platform company Flagship Pioneering. To learn more,
please visit the company's website at www.sendabiosciences.com.
Nestlé Health Science (NHSc), a wholly-owned subsidiary
of Nestlé, is a globally recognized leader in the field of
nutritional science. At NHSc we are committed to empowering
healthier lives through nutrition for consumers, patients and their
healthcare partners. We offer an extensive consumer health
portfolio of industry-leading medical nutrition, consumer and VMS
brands that are science-based solutions covering all facets of
health from prevention, to maintenance, all the way through to
treatment. Headquartered in Switzerland, NHSc employs over
5,000 people around the world who are committed to making a
difference in people's lives, for a healthier today and
tomorrow.
CONTACT: press@sendabiosciences.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/senda-biosciences-and-nestle-health-science-announce-exclusive-global-development--option-agreement-for-sendas-intersystems-biology-based-metabolic-health-products-301215026.html
SOURCE Senda Biosciences